Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.

Breast neoplasms Budget impact analysis Cost Digital breast tomosynthesis Digital mammography Mass screening

Journal

La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625

Informations de publication

Date de publication:
20 Aug 2024
Historique:
received: 19 03 2024
accepted: 04 07 2024
medline: 20 8 2024
pubmed: 20 8 2024
entrez: 20 8 2024
Statut: aheadofprint

Résumé

This study quantifies the impact on budget and cost per health benefit of implementing digital breast tomosynthesis (DBT) in place of digital mammography (DM) for breast cancer screening among asymptomatic women in Italy. A budget impact analysis and a cost consequence analysis were conducted using parameters from the MAITA project and literature. The study considered four scenarios for DBT implementation, i.e., DBT for all women, DBT for women aged 45-49 years, DBT based on breast density (BI-RADS C + D or D only), and compared these to the current DM screening. Healthcare provider's perspective was adopted, including screening, diagnosis, and cancer treatment costs. Introducing DBT for all women would increase overall screening costs by 20%. Targeting DBT to women aged 45-49 years or with dense breasts would result in smaller cost increases (3.2% for age-based and 1.4-10.7% for density-based scenarios). The cost per avoided interval cancer was significantly higher when DBT was applied to all women compared to targeted approaches. The cost per gained early-detected cancer slightly increases in targeted approaches, while the assumptions on the clinical significance and overdiagnosis of cancers detected by DBT and not by DM have a strong impact. Implementing DBT as a primary breast cancer test in screening programs in Italy would lead to a substantial increase in costs. Tailoring DBT use to women aged 45-49 or with dense breasts could enhance the feasibility and sustainability of the intervention. Further research is needed to clarify the impact of DBT on overdiagnosis and the long-term outcomes.

Identifiants

pubmed: 39162938
doi: 10.1007/s11547-024-01850-7
pii: 10.1007/s11547-024-01850-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : RF-2016-02363686

Investigateurs

Chiara Coriani (C)
Manuela Pescarolo (M)
Gloria Stefanelli (G)
Giulio Tondelli (G)
Filippo Beretti (F)
Sabrina Caffarri (S)
Vanessa Marchesi (V)
Laura Canovi (L)
Marco Colli (M)
Mirco Boschini (M)
Marco Bertolini (M)
Moira Ragazzi (M)
Pierpaolo Pattacini (P)
Paolo Giorgi Rossi (P)
Valentina Iotti (V)
Vladimiro Ginocchi (V)
Sara Ravaioli (S)
Rita Vacondio (R)
Cinzia Campari (C)
Stefania Caroli (S)
Andrea Nitrosi (A)
Luca Braglia (L)
Silvio Cavuto (S)
Pamela Mancuso (P)
Olivera Djuric (O)
Francesco Venturelli (F)
Massimo Vicentini (M)
Maria Barbara Braghiroli (MB)
Annamaria Pezzarossi (A)
Jasmine Lonetti (J)
Elena Davoli (E)
Efrem Bonelli (E)
Francesca Fornasa (F)
Giovanna Romanucci (G)
Ilaria Lucchi (I)
Gessica Martello (G)
Claudia Rossati (C)
Stefania Montemezzi (S)
Paola Mantellini (P)
Daniela Ambrogetti (D)
Anna Iossa (A)
Eva Carnesciali (E)
Vincenzo Mazzalupo (V)
Patrizia Falini (P)
Donella Puliti (D)
Marco Zappa (M)
Francesca Battisti (F)
Noemi Auzzi (N)
Simona Verdi (S)
Carolina Degl'Innocenti (C)
Daniela Tramalloni (D)
Elena Cavazza (E)
Simone Busoni (S)
Elisa Betti (E)
Fiorella Ciuffi (F)
Francesca Peruzzi (F)
Francesco Regini (F)
Francesco Sardanelli (F)
Giovanni Di Leo (G)
Luca Alessandro Carbonaro (LA)
Veronica Magni (V)
Andrea Cozzi (A)
Diana Spinelli (D)
Cristian Giuseppe Monaco (CG)
Simone Schiaffino (S)
Adrienn Benedek (A)
Laura Menicagli (L)
Raffaella Ferraris (R)
Elisabetta Favettini (E)
Davide Dettori (D)
Paolo Falco (P)
Pietro Presti (P)
Nereo Segnan (N)
Antonio Ponti (A)
Alfonso Frigerio (A)
Paola Armaroli (P)
Loredana Correale (L)
Vincenzo Marra (V)
Luisella Milanesio (L)
Franca Artuso (F)
Aurora Di Leo (A)
Isabella Castellano (I)
Emilia Riggi (E)
Denise Casella (D)
Sabina Pitarella (S)
Viviana Vergini (V)
Livia Giordano (L)
Stephen W Duffy (SW)
Axel Graewingholt (A)
Kristina Lang (K)
Fabio Falcini (F)
Daniela Ambrogetti (D)
Laura Bonvicini (L)
Beniamino Brancato (B)
Matteo Capobussi (M)
Eva Carnesciali (E)
Marco Moschetta (M)
Elena Parmelli (E)
Loredana Pau (L)
Stella Pedilarco (S)
Francesca Pietribiasi (F)
Ferretti Stefano (F)

Informations de copyright

© 2024. Italian Society of Medical Radiology.

Références

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15–23
pubmed: 36084384 pmcid: 9465273 doi: 10.1016/j.breast.2022.08.010
Alabousi M, Wadera A, Kashif Al-Ghita M, Kashef Al-Ghetaa R, Salameh JP, Pozdnyakov A et al (2021) Performance of digital breast tomosynthesis, synthetic mammography, and digital mammography in breast cancer screening: a systematic review and meta-analysis. J Natl Cancer Inst 113(6):680–690
pubmed: 33372954 doi: 10.1093/jnci/djaa205
Gao Y, Moy L, Heller SL (2021) Digital breast tomosynthesis: update on technology, evidence, and clinical practice. Radiographics 41(2):321–337
pubmed: 33544665 doi: 10.1148/rg.2021200101
Ko MJ, Park DA, Kim SH, Ko ES, Shin KH, Lim W, Kwak BS, Chang JM (2021) Accuracy of digital breast tomosynthesis for detecting breast cancer in the diagnostic setting: a systematic review and meta-analysis. Korean J Radiol 22(8):1240–1252
pubmed: 34047504 pmcid: 8316775 doi: 10.3348/kjr.2020.1227
Pattacini P, Nitrosi A, Giorgi Rossi P, Duffy SW, Iotti V, Ginocchi V et al (2022) A randomized trial comparing breast cancer incidence and interval cancers after tomosynthesis plus mammography versus mammography alone. Radiology 303(2):256–266
pubmed: 35103537 doi: 10.1148/radiol.211132
Gilbert FJ, Tucker L, Young KC (2016) Digital breast tomosynthesis (DBT): a review of the evidence for use as a screening tool. Clin Radiol 71(2):141–150
pubmed: 26707815 doi: 10.1016/j.crad.2015.11.008
ECIBC. European breast cancer guidelines, screening tests: use of tomosynthesis. 2022. European Commission Initiative on Breast Cancer. Last update: 17/06/2022. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/screening-tests
Moger TA, Swanson JO, Holen ÅS, Hanestad B, Hofvind S (2019) Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway. Eur J Health Econ 20(8):1261–1269
pubmed: 31399773 pmcid: 6803617 doi: 10.1007/s10198-019-01094-7
Moger TA, Holen Å, Hanestad B, Hofvind S (2022) Costs and effects of implementing digital tomosynthesis in a population-based breast cancer screening program: predictions using results from the To-Be Trial in Norway. Pharmacoecon Open 6(4):495–507
pubmed: 35796950 pmcid: 9283618 doi: 10.1007/s41669-022-00343-5
Cressman S, Mar C, Sam J, Kan L, Lohrisch C, Spinelli JJ (2021) The cost-effectiveness of adding tomosynthesis to mammography-based breast cancer screening: an economic analysis. CMAJ Open 9(2):E443–E450
pubmed: 33888549 pmcid: 8101637 doi: 10.9778/cmajo.20200154
Slanetz PJ (2020) Digital breast tomosynthesis screening for breast cancer: it is cost-effective! Radiology 297(1):49–50
pubmed: 32772875 doi: 10.1148/radiol.2020202779
Sankatsing VDV, Juraniec K, Grimm SE, Joore MA, Pijnappel RM, de Koning HJ, van Ravesteyn NT (2020) Cost-effectiveness of digital breast tomosynthesis in population-based breast cancer screening: a probabilistic sensitivity analysis. Radiology 297(1):40–48
pubmed: 32749212 doi: 10.1148/radiol.2020192505
Wang J, Phi XA, Greuter MJW, Daszczuk AM, Feenstra TL, Pijnappel RM, Vermeulen KM, Buls N, Houssami N, Lu W, de Bock GH (2020) The cost-effectiveness of digital breast tomosynthesis in a population breast cancer screening program. Eur Radiol 30(10):5437–5445
pubmed: 32382844 pmcid: 7476964 doi: 10.1007/s00330-020-06812-x
Thompson W, Argaez C (2019) Digital breast tomosynthesis for the screening and diagnosis of breast cancer: a review of the diagnostic accuracy, cost-effectiveness and guidelines [internet]. Canadian Agency for Drugs and Technologies in Health, Ottawa
Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, Barlow WE, Burnside ES et al (2020) Long-term outcomes and cost-effectiveness of breast cancer screening with digital breast tomosynthesis in the United States. J Natl Cancer Inst 112(6):582–589
pubmed: 31503283 doi: 10.1093/jnci/djz184
Movik E, Dalsbø TK, Fagelund BC, Friberg EG, Håheim LL, Skår Å (2017) Digital breast tomosynthesis with hologic 3D mammography selenia dimensions system for use in breast cancer screening: a single technology assessment [internet]. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH), Oslo, Norway. Report from the Norwegian Institute of Public Health No. 2017-08
Hunter SA, Morris C, Nelson K, Snyder BJ, Poulton TB (2017) Digital breast tomosynthesis: cost-effectiveness of using private and medicare insurance in community-based health care facilities. AJR Am J Roentgenol 208(5):1171–1175
pubmed: 28177646 doi: 10.2214/AJR.16.16987
Miller JD, Bonafede MM, Herschorn SD, Pohlman SK, Troeger KA, Fajardo LL (2017) Value analysis of digital breast tomosynthesis for breast cancer screening in a US medicaid population. J Am Coll Radiol 14(4):467-474.e5
pubmed: 28139412 doi: 10.1016/j.jacr.2016.11.019
Kalra VB, Wu X, Haas BM, Forman HP, Philpotts LE (2016) Cost-effectiveness of tomosynthesis in annual screening mammography. AJR Am J Roentgenol 207(5):1152–1155
pubmed: 27547861 doi: 10.2214/AJR.15.14487
Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD (2015) Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 274(3):772–780
pubmed: 25350548 doi: 10.1148/radiol.14141237
Richman IB, Hoag JR, Xu X et al (2019) Adoption of digital breast tomosynthesis in clinical practice. JAMA Intern Med 179(9):1292–1295
pubmed: 31233086 pmcid: 6593646 doi: 10.1001/jamainternmed.2019.1058
Battisti F, Mantellini P, Falini P, Ventura L, Giordano L, Saguatti G, Zappa M, Deandrea S, Gorini G (2022) Key performance indicators of breast cancer screening programmes in Italy, 2011–2019. Ann Ist Super Sanita 58(4):244–253
pubmed: 36511195
Bernardi D, Belli P, Benelli E, Brancato B, Bucchi L, Calabrese M, Carbonaro LA, Caumo F, Cavallo-Marincola B, Clauser P, Fedato C, Frigerio A, Galli V, Giordano L, Giorgi Rossi P, Golinelli P, Morrone D, Mariscotti G, Martincich L, Montemezzi S, Naldoni C, Paduos A, Panizza P, Pediconi F, Querci F, Rizzo A, Saguatti G, Tagliafico A, Trimboli RM, Zappa M, Zuiani C, Sardanelli F (2017) Digital breast tomosynthesis (DBT): recommendations from the Italian College of Breast Radiologists (ICBR) by the Italian Society of Medical Radiology (SIRM) and the Italian Group for Mammography Screening (GISMa). Radiol Med 122(10):723–730
pubmed: 28540564 pmcid: 5596055 doi: 10.1007/s11547-017-0769-z
Bernardi D, Gentilini MA, De Nisi M, Pellegrini M, Fantò C, Valentini M, Sabatino V, Luparia A, Houssami N (2020) Effect of implementing digital breast tomosynthesis (DBT) instead of mammography on population screening outcomes including interval cancer rates: results of the Trento DBT pilot evaluation. Breast 50:135–140
pubmed: 31607526 doi: 10.1016/j.breast.2019.09.012
The National Guidelines System of the Italian National Institute of Health (2024) Guidelines for the breast cancer screening and diagnosis (ADOLOPMENT of the European guidelines). https://www.iss.it/documents/20126/9314965/LG+507_Screening+e+diagnosi+tumore+mammella_parte+3.pdf/25fa934b-576c-83d4-bc9f-3f5ad5d626ea?t=1712220698175 . [Italian] LINEE GUIDA PER LO SCREENING E LA DIAGNOSI DEL TUMORE DELLA MAMMELLA (ADOLOPMENT LINEE GUIDA EUROPEE) Capitolo sull’uso della tomosintesi
Giorgi Rossi P, Mancuso P, Pattacini P, Campari C, Nitrosi A, Iotti V et al (2024) Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium. Eur J Cancer 199:113553.
pubmed: 38262307 doi: 10.1016/j.ejca.2024.113553
Istituto per lo Studio e la Prevenzione Oncologia. Linea guida: “Screening e diagnosi del tumore della mammella (Adolopment LG Europee) - Raccomandazioni fasce di età e intervalli”. Sistema Nazionale Linee Guida dell’Istituto Superiore di Sanità. 2022
Armaroli P, Frigerio A, Correale L, Ponti A, Artuso F, Casella D et al (2022) A randomised controlled trial of digital breast tomosynthesis vs digital mammography as primary screening tests: Screening results over subsequent episodes of the Proteus Donna study. Int J Cancer 151(10):1778–1790
pubmed: 35689673 doi: 10.1002/ijc.34161
Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17(1):5–14
pubmed: 24438712 doi: 10.1016/j.jval.2013.08.2291
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S (2022) Correction to: Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy 20(5):781–782. https://doi.org/10.1007/s40258-022-00743-y . (Erratum for: Appl Health Econ Health Policy. 2022 Ma;20(2):213-221)
doi: 10.1007/s40258-022-00743-y pubmed: 35840812 pmcid: 9385799
ONS. I costi dello screening. Libro a cura di Paola Mantellini e Giuseppe Lippi. Osservatorio Nazionale Screening. 2011. Disponibile all’indirizzo: https://www.osservatorionazionalescreening.it/sites/default/files/allegati/Mantellini_PDF_navigabile.pdf . Accessed 2 Nov 2023
Francisci S, Guzzinati S, Capodaglio G, Pierannunzio D, Mallone S, Tavilla A et al (2020) Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data. Eur J Health Econ 21(7):1003–1013
pubmed: 32399781 doi: 10.1007/s10198-020-01190-z
Khan SA, Hernandez-Villafuerte K, Hernandez D, Schlander M (2023) Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach. Front Public Health 10:946544
pubmed: 36684975 pmcid: 9853539 doi: 10.3389/fpubh.2022.946544
Giorgi Rossi P, Djuric O, Hélin V, Astley S, Mantellini P, Nitrosi A et al (2021) Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk. Sci Rep 11(1):19884
pubmed: 34615978 pmcid: 8494838 doi: 10.1038/s41598-021-99433-3
Puliti D, Zappa M, Giorgi Rossi P, Pierpaoli E, Manneschi G, Ambrogetti D et al (2018) Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort study. Breast Cancer Res 20(1):95
pubmed: 30092817 pmcid: 6085631 doi: 10.1186/s13058-018-1025-8
Giorgi Rossi P, Mancuso P, Pattacini P, Campari C, Nitrosi A, Iotti V, Ponti A, Frigerio A, Correale L, Riggi E, Giordano L, Segnan N, Di Leo G, Magni V, Sardanelli F, Fornasa F, Romanucci G, Montemezzi S, Falini P, Auzzi N, Zappa M, Ottone M, Mantellini P, Duffy SW, Armaroli P, MAITA working group.; following are also members of the MAITA working group, Coriani C, Pescarolo M, Stefanelli G, Tondelli G, Beretti F, Caffarri S, Marchesi V, Canovi L, Colli M, Boschini M, Bertolini M, Ragazzi M, Pattacini P, Giorgi Rossi P, Iotti V, Ginocchi V, Ravaioli S, Vacondio R, Campari C, Caroli S, Nitrosi A, Braglia L, Cavuto S, Mancuso P, Djuric O, Venturelli F, Vicentini M, Braghiroli MB, Lonetti J, Davoli E, Bonelli E, Fornasa F, Montemezzi S, Romanucci G, Lucchi I, Martello G, Rossati C, Mantellini P, Ambrogetti D, Iossa A, Carnesciali E, Mazzalupo V, Falini P, Puliti D, Zappa M, Battisti F, Auzzi N, Verdi S, Degl’Innocenti C, Tramalloni D, Cavazza E, Busoni S, Betti E, Peruzzi F, Regini F, Sardanelli F, Di Leo G, Carbonaro LA, Magni V, Cozzi A, Spinelli D, Monaco CG, Schiaffino S, Benedek A, Menicagli L, Ferraris R, Favettini E, Dettori D, Falco P, Presti P, Segnan N, Ponti A, Frigerio A, Armaroli P, Correale L, Marra V, Milanesio L, Artuso F, Di Leo A, Castellano I, Riggi E, Casella D, Pitarella S, Vergini V, Giordano L, Duffy SW, Graewingholt A, Lang K, Falcini F (2024) Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium. Eur J Cancer 199:113553
pubmed: 38262307 doi: 10.1016/j.ejca.2024.113553
Hofvind S, Moshina N, Holen ÅS, Danielsen AS, Lee CI, Houssami N, Aase HS, Akslen LA, Haldorsen IS (2021) Interval and subsequent round breast cancer in a randomized controlled trial comparing digital breast tomosynthesis and digital mammography screening. Radiology 300(1):66–76
pubmed: 33973840 doi: 10.1148/radiol.2021203936
Farber R, Houssami N, Wortley S, Jacklyn G, Marinovich ML, McGeechan K, Barratt A, Bell K (2021) Impact of full-field digital mammography versus film-screen mammography in population screening: a meta-analysis. J Natl Cancer Inst 113(1):16–26
pubmed: 32572492 doi: 10.1093/jnci/djaa080
Ronco G, Segnan N (2007) HPV testing for primary cervical cancer screening. Lancet 370(9601):1740–1742. https://doi.org/10.1016/S0140-6736(07)61480-9
doi: 10.1016/S0140-6736(07)61480-9 pubmed: 17919717
Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, Giordano L, Frigerio A, Törnberg S, EUNICE Project and Euroscreen Working Groups, Van Hal G, Martens P, Májek O, Danes J, von Euler-Chelpin M, Aasmaa A, Anttila A, Becker N, Péntek Z, Budai A, Mádai S, Fitzpatrick P, Mooney T, Zappa M, Ventura L, Scharpantgen A, Hofvind S, Seroczynski P, Morais A, Rodrigues V, Bento MJ, Gomes de Carvalho J, Natal C, Prieto M, Sánchez-Contador Escudero C, Zubizarreta Alberti R, Fernández Llanes SB, Ascunce N, Ederra Sanza M, Sarriugarte Irigoien G, Salas Trejo D, Ibáñez Cabanell J, Wiege M, Ohlsson G, Törnberg S, Korzeniewska M, de Wolf C, Fracheboud J, Patnick J, Lancucki L, Ducarroz S, Suonio E (2012) False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen 19(Suppl 1):57–66
pubmed: 22972811 doi: 10.1258/jms.2012.012083
Hofvind S, Holen ÅS, Aase HS, Houssami N, Sebuødegård S, Moger TA et al (2019) Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. Lancet Oncol 20(6):795–805
pubmed: 31078459 doi: 10.1016/S1470-2045(19)30161-5
Houssami N, Hofvind S, Soerensen AL, Robledo KP, Hunter K, Bernardi D et al (2021) Interval breast cancer rates for digital breast tomosynthesis versus digital mammography population screening: an individual participant data meta-analysis. EClinicalMedicine 34:100804
pubmed: 33997729 pmcid: 8102709 doi: 10.1016/j.eclinm.2021.100804
Sankatsing VDV, Fracheboud J, de Munck L, Broeders MJM, van Ravesteyn NT, Heijnsdijk EAM et al (2018) Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening. BMC Cancer 18(1):256
pubmed: 29506487 pmcid: 5839006 doi: 10.1186/s12885-018-4122-2
Sprague BL, Coley RY, Lowry KP, Kerlikowske K, Henderson LM, Su YR et al (2023) Digital breast tomosynthesis versus digital mammography screening performance on successive screening rounds from the breast cancer surveillance consortium. Radiology 307(5):e223142
pubmed: 37249433 doi: 10.1148/radiol.223142
Jayasekera J, Mandelblatt JS (2020) Systematic review of the cost effectiveness of breast cancer prevention, screening, and treatment interventions. J Clin Oncol 38(4):332–350
pubmed: 31804858 doi: 10.1200/JCO.19.01525
Magni V, Cozzi A, Schiaffino S, Colarieti A, Sardanelli F (2023) Artificial intelligence for digital breast tomosynthesis: impact on diagnostic performance, reading times, and workload in the era of personalized screening. Eur J Radiol 158:110631
pubmed: 36481480 doi: 10.1016/j.ejrad.2022.110631
Sorin V, Sklair-Levy M (2019) Dual-energy contrast-enhanced spectral mammography (CESM) for breast cancer screening. Quant Imaging Med Surg 9(11):1914–1917
pubmed: 31867243 pmcid: 6902143 doi: 10.21037/qims.2019.10.13
Henderson JT, Webber EM, Weyrich MS, Miller M, Melnikow J (2024) Screening for breast cancer: evidence report and systematic review for the US preventive services task force. JAMA 331(22):1931–1946
pubmed: 38687490 doi: 10.1001/jama.2023.25844
US Preventive Services Task Force, Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, Davis EM, Jaén CR, Krousel-Wood M, Lee S, Li L, Mangione CM, Rao G, Ruiz JM, Stevermer JJ, Tsevat J, Underwood SM, Wiehe S (2024) Screening for breast cancer: US preventive services task force recommendation statement. JAMA 331(22):1918–1930
doi: 10.1001/jama.2024.5534

Auteurs

Olivera Djuric (O)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Centre for Environmental, Nutritional and Genetic Epidemiology (CREAGEN), University of Modena and Reggio Emilia, Modena, Italy.

Silvia Deandrea (S)

Pavia Health Protection Agency, Pavia, Italy.

Paola Mantellini (P)

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.

Francesco Sardanelli (F)

IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Francesco Venturelli (F)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Stefania Montemezzi (S)

Radiology Unit - University Hospital of Verona, Verona, Italy.

Riccardo Vecchio (R)

Pavia Health Protection Agency, Pavia, Italy.

Lauro Bucchi (L)

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Forlì-Cesena, Italy.

Carlo Senore (C)

AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.

Livia Giordano (L)

AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.

Eugenio Paci (E)

Italian Cancer League, LILT, Florence, Italy.

Adriana Bonifacino (A)

Fondazione IncontraDonna, Rome, Italy.

Massimo Calabrese (M)

Breast Unit. IRCCS-Policlinico San Martino, Genoa, Italy.

Francesca Caumo (F)

Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy.

Flori Degrassi (F)

Associazione Nazionale Donne Operate al Seno - ANDOS, Milan, Italy.

Priscilla Sassoli De' Bianchi (P)

Department of Health, Emilia-Romagna Region Administration, Bologna, Italy.

Francesca Battisti (F)

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.

Marco Zappa (M)

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.

Pierpaolo Pattacini (P)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Cinzia Campari (C)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Andrea Nitrosi (A)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Giovanni Di Leo (G)

IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Alfonso Frigerio (A)

AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.

Veronica Magni (V)

IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Francesca Fornasa (F)

Breast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy.

Giovanna Romanucci (G)

Breast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy.

Patrizia Falini (P)

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.

Noemi Auzzi (N)

ISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.

Paola Armaroli (P)

AOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.

Paolo Giorgi Rossi (P)

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy. paolo.giorgirossi@ausl.re.it.

Classifications MeSH